Is Gennex Lab. overvalued or undervalued?

As of 27 October 2025, Gennex Lab's valuation grade has moved from very attractive to fair, indicating a shift in market perception. The company is currently fairly valued, with a price-to-earnings (PE) ratio of 22.54, a price-to-book value of 2.06, and an EV to EBITDA ratio of 15.83. These ratios suggest that while the company is not undervalued, it is also not significantly overvalued compared to its peers.
In comparison to its industry peers, Gennex Lab's PE ratio is lower than that of Sun Pharma, which is considered expensive at 35.43, and Divi's Lab, which is very expensive at 74.62. On the other hand, it is slightly higher than Cipla, which has a PE of 23.74 and is rated attractive. Notably, Gennex Lab has outperformed the Sensex over the last three years with a return of 166.72% compared to the Sensex's 41.87%, but it has underperformed over the past year with a decline of 20.32% against the Sensex's gain of 6.77%.